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Background: Herpes simplex virus type 2 (HSV-2) infection is a prevalent, sexually transmitted infection with
a sizable disease burden that is highest in sub-Saharan Africa. This study aimed to characterize HSV-2 epide-
miology in this region.
Methods: Cochrane and PRISMA guidelines were followed to systematically review, synthesize, and report
HSV-2 related findings up to August 23, 2020. Meta-analyses and meta-regressions were conducted.
Findings: From 218 relevant publications, 451 overall outcome measures and 869 stratified measures were
extracted. Pooled incidence rates ranged between 2.419.4 per 100 person-years across populations. Pooled
seroprevalence was lowest at 37.3% (95% confidence interval (CI): 34.939.7%) in general populations and
high in female sex workers and HIV-positive individuals at 62.5% (95% CI: 54.870.0%) and 71.3% (95% CI:
66.575.9%), respectively. In general populations, pooled seroprevalence increased steadily with age. Com-
pared to women, men had a lower seroprevalence with an adjusted risk ratio (ARR) of 0.61 (95% CI:
0.560.67). Seroprevalence has decreased in recent decades with an ARR of 0.98 (95% CI: 0.970.99) per
year. Seroprevalence was highest in Eastern and Southern Africa. Pooled HSV-2 proportion in genital ulcer
disease was 50.7% (95% CI: 44.756.8%) and in genital herpes it was 97.3% (95% CI: 84.4100%).
Interpretation: Seroprevalence is declining by 2% per year, but a third of the population is infected. Age and
geography play profound roles in HSV-2 epidemiology. Temporal declines and geographic distribution of
HSV-2 seroprevalence mirror that of HIV prevalence, suggesting sexual risk behavior has been declining for
three decades. HSV-2 is the etiological cause of half of genital ulcer disease and nearly all genital herpes cases
with limited role for HSV-1.
Funding: This work was supported by pilot funding from the Biomedical Research Program at Weill Cornell
Medicine in Qatar and by the Qatar National Research Fund [NPRP 90403008].
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Herpes simplex virus type 2 (HSV-2) infection is a highly
prevalent, sexually transmitted infection (STI) worldwide [1]. It
is a leading cause of genital ulcer disease (GUD) and genital her-
pes, manifesting in the form of painful, recurrent, and frequentgenital lesions [28]. Its vertical transmission from mother-to-
child can lead to neonatal herpes, a severe and sometimes fatal
outcome in newborns [3,9]. HSV-2 is linked to a 2- to 3-fold
increase in sexual transmission and acquisition of HIV [1012],
implying potential epidemiological synergy between the two
viruses [11,13,14].
HSV-2 is typically asymptomatic in most of those who acquire
it [3]. Its chronic and reactivating nature, as well as its subclinical
shedding [15,16], increase its rate of transmission and lead to
high antibody prevalence (seroprevalence) among general and
higher-risk populations alike [11,17,18]. Since HSV-2 is more
transmissible than HIV and produces long-lasting antibodies, it
Research in context
Evidence before this study
Herpes simplex virus type 2 (HSV-2) infection is a highly preva-
lent sexually transmitted infection (STI) worldwide, and results
in a sizable disease burden. Despite breadth of empirical evi-
dence for this infection, a PubMed search using the search crite-
ria ("Herpes Simplex" [MeSH] AND "Review" [Publication
Type]) yielded no regional in-depth, robust systematic review
and meta-analytical assessment regarding the epidemiology of
this infection in sub-Saharan Africa or elsewhere.
Added value of this study
Based on a large body of identified evidence, the study provided
estimates for HSV-2 incidence rate, seroprevalence, and pro-
portion of HSV-2 detection in genital ulcer disease (GUD) and
in genital herpes. The study also established epidemiological
associations relevant for Africa and elsewhere. Seroprevalence
was declining rapidly by 2% per year, yet still remains high with
a third of the population infected. The study further docu-
mented HSV-2 as the etiological cause of half of GUD cases and
nearly all of genital herpes cases in this part of the world.
Implications of all the available evidence
HSV-2 infection and its adverse health outcomes are wide-
spread in sub-Saharan Africa, more so than any other
region, yet despite this disease burden, this infection
remains uncontrolled with the absence of any specific or
targeted public health program to prevent and control geni-
tal herpes. In the context of serious consequences for repro-
ductive, sexual, and psychosocial health, the study findings
demonstrate an urgent need for both prophylactic and ther-
apeutic HSV-2 vaccines, and argue for the acceleration of
ongoing efforts to develop a vaccine. The findings further
provide concrete evidence and analytical knowledge
towards building a business case for the global public health
value of HSV-2 vaccines.
2 M. Harfouche et al. / EClinicalMedicine 35 (2021) 100876has been used as an objective biological marker of sexual risk
behavior and risk of HIV infection [1923]. Analyses using empir-
ical data and mathematical modeling supported the utility of
using HSV-2 seroprevalence to predict HIV epidemic potential
[19,20,24].
Inadequate understanding of HSV-2 epidemiology and HSV-20s
considerable consequences on sexual and reproductive health and
the HIV epidemic [11,13], call for further research and urgent
preventive and control measures. The World Health Organization
(WHO) outlined a “Global Health Sector Strategy on STIs,
2016202100 [25] to eliminate STIs as a main public health con-
cern by 2030 through integration of preventive and control meas-
ures. Consequently, WHO, along with its global partners, is
spearheading efforts to develop an HSV vaccine as an urgent pri-
ority [26,27].
To inform these efforts, we conducted a systematic review to
characterize HSV-2 infection levels and trends in sub-Saharan
Africa (SSA), the hub of the HIV epidemic [28,29]. We estimated
pooled means for each outcome measure (incidence rate, sero-
prevalence, proportion of HSV-2 in GUD, and proportion of HSV-2
in genital herpes) across populations and subpopulations. We
also conducted meta-regression analyses to assess temporal
trends and to identify predictors of high seroprevalence and
between-study heterogeneity.2. Methodology
2.1. Data sources and search strategy
This systematic review was guided by the Cochrane Collaboration
Handbook [30] and was reported according to the Preferred Report-
ing Items for Systematic Reviews and Meta-analyses (PRISMA) guide-
lines [31]. The review was informed by the methodology applied
recently in a series of systematic reviews for HSV-1 infection
[3236].
All available publications were systematically reviewed up to
August 23, 2020. The search was conducted in PubMed and Embase
databases, using search strategies with exploded MeSH/Emtree
terms, broad search criteria, without language or date restrictions to
widen the scope and include all subheadings (Table S1). The defini-
tion of Africa included 45 countries, as defined by WHO for the Afri-
can Region [37], covering countries of sub-Saharan Africa. The list of
countries and their subregional stratification is in Box S1.
2.2. Study selection and eligibility criteria
Search results were imported into the reference manager Endnote
(Thomson Reuters, USA), whereby duplicate publications were iden-
tified and removed. The remaining records were screened for rele-
vance based on titles and abstracts, followed by full text screening of
relevant and potentially relevant records. Additional bibliography
screening was performed on both reviews and the relevant articles to
identify any missing publications.
Inclusion criteria were met if publications reported primary data
on any of the following four outcomes: 1) HSV-2 incidence rate, 2)
HSV-2 seroprevalence, 3) proportion of HSV-2 detection in GUD, and
4) proportion of HSV-2 detection in genital herpes. A sample size of
10 was required for inclusion for all outcome measures. Exclusion
criteria encompassed case reports, series, commentaries, reviews,
and qualitative studies. In this review, “publication” refers to a docu-
ment reporting any outcome measure, whilst a “study” refers to
details of a specific outcome measure. Special care was given to
ensure that overlapping studies were only included once by search-
ing the extraction database for any potential overlap in years of publi-
cation, years of data collection, study authors, and study locations.
2.3. Data extraction and synthesis
MH and FA each extracted half of the studies. Subsequently, MH
double-extracted and reviewed studies extracted by FA and FA did
the same for those extracted by MH. Discrepancies were discussed in
consultation with LJA to reach consensus. A list of extracted variables
is in Box S2.
Overall outcome measures and their stratified measures were
extracted, provided that the stratification agreed with a pre-set strat-
ification hierarchy and the subsample in each stratum was 10. The
pre-set stratification hierarchy sequence for incidence and seropreva-
lence measures was as follows: population type (see Box S3 for defi-
nition), sex, and age. As for proportion of HSV-2 detection in GUD
and genital herpes, the sequence was: genital herpes episode status
(primary versus recurrent episode), sex, age, and study site (hospital
versus outpatient clinic).
Measures reporting any HSV-2 outcome among children
<15 years old were only reported, and not included in the analyses.
2.4. Quality assessment
Relevant studies were subjected to a quality pre-assessment to
evaluate the validity of the assays used, given their limitations
[38,39]. This assessment was done with the help of an expert from
the University of Washington, Professor Rhoda Ashley-Morrow, who
M. Harfouche et al. / EClinicalMedicine 35 (2021) 100876 3assessed the quality of study diagnostic methods. Only studies with
valid, sensitive, and specific assays were included in the review.
These studies were then evaluated using the Cochrane approach for
risk of bias (ROB) assessment [30]. Study precision was classified as
either low or high based on the study sample size (<100 versus
100) [40]. Studies were classified as either low or high ROB using
two quality domains: sampling method (probability versus non-prob-
ability based sampling) and response rate (80% versus <80% or
unclear). Effect of ROB on study outcome was investigated through
meta-regression as noted below.
2.5. Meta-analyses
Pooled mean estimates for all four outcomes were calculated
across all strata using meta-analyses, provided each stratum had 3
measures. Only studies reporting incidence rate by person-time were
included in the meta-analyses. Log transformed incidence rates were
used to calculate pooled estimates using the inverse variance method
in the metarate function [41,42]. HSV-2 seroprevalence measures
and proportions of HSV-2 detection in GUD and in genital herpes
were each pooled using the DerSimonian-Laird random-effects
model [41], applying the Freeman-Tukey double arcsine transforma-
tion to stabilize the variance [43], and factoring knowledge of the
applicability of this transformation [44]. Random-effects meta-analy-
ses were used to account for the potential existence of heterogeneity
in effect size arising from clinical differences in study participants or
study methodological differences (such as diagnostic method, sam-
pling method, and response rate). Existence of heterogeneity in effect
size was assessed using Cochran's Q statistic [41,45]. The magnitude
of between-study variation attributed to true differences in effect
size, as opposed to chance, was measured using I2 [41,45]. Distribu-
tions of true measures around the pooled mean were described using
the prediction interval. Sources of heterogeneity were investigated
through meta-regressions. Meta-analyses were conducted in R ver-
sion 3.4.1 [46] using the meta package [42].
2.6. Meta-regressions
Univariable and multivariable random-effects meta-regression
analyses were conducted using log-transformed seroprevalence
measures to examine factors and predictors potentially associated
with increased HSV-2 seroprevalence, as well as sources of between-
study heterogeneity. Pre-set variables included in these analyses are
listed in Box S4. Factors included in multivariable models had to have
a p-value<0.1 in the univariable model. Strength of evidence for an
association was deemed significant for factors with a p-value<0.05 in
the multivariable models. Meta-regressions were conducted in Stata/
SE version 13 [47] using the metareg package [48].
2.7. Role of the funding source
The funder of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the article. The
corresponding author had full access to all data in the study and had
the final responsibility for the decision to submit for publication.
3. Results
3.1. Search results and scope of evidence
Fig. 1 depicts the PRISMA flowchart describing the study selection
process [31]. A total of 14,830 citations were captured in the initial
search (2039 from PubMed and 12,791 from Embase). After dedupli-
cation, title and abstract screening, and full text screening, 205 rele-
vant publications were identified. Thirteen additional publications,including country level reports, were identified through bibliography
screening [4961].
In total, 218 publications met the inclusion criteria. Extracted
measures encompassed 47 seroconversion rates, 48 overall (65 strati-
fied) incidence rates, 322 overall (773 stratified) seroprevalence
measures, 25 overall (31 stratified) proportions of HSV-2 detection in
GUD, and 9 overall (11 stratified) proportions of HSV-2 detection in
genital herpes.
3.2. Incidence overview and pooled mean estimates for HSV-2 incidence
rate
Table S2 summarizes extracted seroconversion and incidence
rates. Studies were either longitudinal cohorts (number of measures
(n)=35; 49.3%) or randomized controlled trials (n = 36; 50.7%), with a
follow-up duration ranging between 6 weeks to 6 years. HSV-2 sero-
conversion rates (n = 47), that is cumulative incidence, ranged
between 0.058.0% across studies, reflecting in part the widely vari-
able duration of follow-up.
In general populations, HSV-2 incidence rates among women
(n = 20) ranged from 3.6 to 21.7 per 100 person-years with a median
of 7.5 and a pooled mean of 7.2 (95% confidence interval (CI):
5.59.4) per 100 person-years (Table 1). Among men (n = 20), inci-
dence rate ranged from 1.5 to 10.5 per 100 person-years with a
median of 5.5 and a pooled mean of 4.1 (95% CI: 3.15.3) per 100 per-
son-years. Higher incidence rates were found in higher risk popula-
tions. A summary of pooled mean incidence rate by population type
and associated forest plots are in Table 1 and Figure S1, respectively.
Seroconversion rates were not pooled because follow-up durations
varied so widely that rates were methodologically not comparable.
3.3. Prevalence overview
Tables S3, S4, S5, S6, and S7 summarize overall seroprevalence
measures (n = 322) across the subregions of SSA. The earliest publica-
tion appeared in 1991. Half the studies were published after the year
2010 (n = 176; 55.5%), and most were based on convenience sampling
(n = 233; 72.4%).
For stratified seroprevalence measures, HSV-2 seroprevalence
among general population women (n = 290) ranged from 0.1 to 97.4%
with a median of 43.1%, and among general population men (n = 186)
from 0.0 to 84.2% with a median of 27.5% (Table 2).
In higher-risk populations (n = 40), almost all studies were con-
ducted among female sex workers (FSWs; n = 39) with seropreva-
lence ranging from 4.3 to 99.0% with a median of 65.0% (Table 2).
High seroprevalence was observed in HIV-positive individuals and in
individuals in HIV discordant couples, ranging from 42.0 to 95.2%
with a median of 79.7% among women (n = 20), and from 44.0 to
94.2% with a median of 61.4% among men (n = 15).
Tables 2, 3, and S9 summarize HSV-2 seroprevalence measures for
additional populations and subpopulations, including by population
type, country, subregion, age, sex, and year of publication.
3.4. Pooled mean estimates for HSV-2 seroprevalence
Tables 2, 3, and S8 show results of seroprevalence meta-analyses
across populations and subpopulations. Pooled mean seroprevalence
was lowest at 37.3% (95% CI: 34.939.7%) in general populations
(n = 507), followed by 47.4% (95% CI: 43.251.5%) in HIV-negative
populations (n = 51), 57.1% (95% CI: 50.163.9%) in intermediate-risk
populations (n = 45), 61.2% (95% CI: 56.565.9%) in STI clinic attend-
ees and symptomatic populations (n = 72), 61.4% (95% CI:
53.469.1%) in higher-risk populations (n = 40; mainly FSWs), and
71.3% (95% CI: 66.575.9%) in HIV-positive individuals and in individ-
uals in HIV discordant couples (n = 42; Table 2).
Fig. 1. Flowchart of article selection for the systematic review of HSV-2 infection in sub-Saharan Africa, per PRISMA guidelines [31]
Abbreviations: HSV-2 = Herpes simplex virus type 2.
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ied across African subregions (Table 3), with the lowest being 25.0%
(95% CI: 20.929.4%) in Western Africa (n = 68), followed by 35.8%
(95% CI: 31.640.0%) in Southern Africa (n = 226), 41.9% (95% CI:
38.445.3%) in Eastern Africa (n = 188), and 52.4% (95% CI:
40.464.3%) in Central Africa (n = 25). A similar pattern was observed
across subregions for women and men, with women having consis-
tently higher pooled mean seroprevalences than men (Table S8).
Across age groups (Table 3), pooled mean seroprevalence
increased gradually from 12.4% (95% CI: 10.614.3%) in those <20
years-old (n = 88), followed by 34.2% (95% CI: 30.737.8%) in those
2030 years-old (n = 112), 57.1% (95% CI: 54.863.3%) in those
3040 years-old (n = 69), 64.6% (95% CI: 59.569.5%) in those 4050
years-old (n = 48), and then decreasing slightly to 58.2% (95% CI:
50.365.9%) in those >50 years-old. A similar trend was observed
across age groups for women and men separately, but seroprevalence
grew faster with age for young women (Table S8).Heterogeneity was evident in almost all meta-analyses (p-val-
ue<0.001), and was confirmed by wide prediction intervals (Tables 2,
3, and S8). Most heterogeneity was attributed to true variation in
seroprevalence rather than to chance (I2>50%). The Q statistic was
very large for some pooled measures (>10,000), indicating very
strong evidence for heterogeneity in seroprevalence. Forest plots for
meta-analyses across African subregions stratified by population
type are in Figure S2.3.5. Predictors of HSV-2 seroprevalence
Table 4 shows results of the meta-regression analyses for HSV-2
seroprevalence. Nine variables were eligible for inclusion in the mul-
tivariable model (p-value<0.1 in univariable analysis). Two multivar-
iable models were conducted, one including year of publication as a
categorical variable and one including it as a linear term.
Table 1
Pooled mean estimates for herpes simplex virus type 2 incidence rate among different populations in sub-Saharan Africa.
Population type Outcome measures Samples HSV-2 incidence rate
(per 100 person-years)
Pooled mean HSV-2 incidence rate Heterogeneity measures
Total n Total Range Median Mean (per 100 person-years) Q* I2y (%)
person-years (95% CI) (p-value) (95% CI)
General populations
Women 20 21,607.4 3.621.7 7.5 7.2 (5.59.4) 321.1 (p<0.001) 94.1 (92.195.6)
<25 years old 6 6914.5 4.021.7 9.1 6.7 (4.69.7) 51.5 (p<0.001) 90.3 (81.694.9)
25 years old 3 154.0 9.015.4 9.3 11.4 (7.118.3) 1.1 (p = 0.582) 0.0 (0.080.8)
Mixed ages 11 14,538.9 3.621.0 7.0 6.9 (4.710.1) 257.5 (p<0.001) 96.1 (94.597.3)
Men 20 29,287.3 1.510.5 5.5 4.1 (3.15.3) 250.9 (p<0.001) 92.4 (89.794.4)
<25 years old 6 3841.1 1.510.4 6.5 4.0 (2.37.0) 49.9 (p<0.001) 90.0 (80.994.7)
25 years old 8 1835.2 4.010.5 6.5 6.5 (5.37.9) 7.7 (p = 0.364) 8.6 (0.070.4)
Mixed age 6 23,611.1 1.44.9 5.0 2.4 (1.63.6) 120.0 (p<0.001) 95.8 (93.197.5)
Mixed sexes 5 15,603.7 2.33.6 3.5 3.2 (2.53.7) 17.9 (p = 0.001) 77.7 (46.290.7)
Intermediate-risk populations
Women 3 774.8 14.228.6 17.3 19.4 (11.832.1) 16.8 (p<0.001) 88.1 (66.995.7)
Higher-risk populations
Female sex workers 3 1458.0 8.723.0 21.0 18.0 (13.124.9) 11.2 (p = 0.004) 82.2 (45.294.2)
HIV-negative populations
Mixed sexes 5 5203.0 5.211.0 6.1 7.9 (6.010.5) 31.7 (p<0.001) 87.4 (73.094.1)
HIV-positive individuals and in individuals in HIV discordant couples
Mixed sexes 3 2606.8 5.514.8 7.7 8.6 (4.715.7) 38.2 (p<0.001) 94.8 (88.197.7)
Other populations
Mixed sexes 6 767.3 3.435.1 17.1 14.2 (8.623.6) 27.7 (p<0.001) 82.0 (61.691.5)
* Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in incidence rates.
y I2: a measure that assesses the magnitude of between-study variation that is due to actual differences in incidence rates across studies rather than chance.
Abbreviations: CI = Confidence interval, HIV = human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2.
Table 2
Pooled mean estimates for herpes simplex virus type 2 seroprevalence among the different at risk populations in sub-Saharan Africa, by sex.
Population type Outcome
measures
Sample size HSV-2 seroprevalence (%) Pooled mean HSV-2
seroprevalence
Heterogeneity measures
Total n Total N Range Median Mean (%) (95% CI) Q* (p-value) I2y (%) (95% CI) Prediction
intervalz (%)
General populations 507 230,541 0.097.4 39.5 37.3 (34.939.7) 73,247.9 (p<0.001) 99.3 (99.399.3) 0.788.0
Women 290 134,034 0.197.4 43.1 43.1 (39.846.5) 44,291.3 (p<0.001) 99.3 (99.399.4) 1.892.4
Men 186 83,898 0.084.2 27.5 29.1 (25.732.6) 21,577.1 (p<0.001) 99.1 (99.199.2) 0.177.7
Mixed 31 12,609 1.390.9 33.9 32.5 (27.337.8) 975.5 (p<0.001) 96.9 (96.397.4) 8.462.9
Intermediate-risk
populations
45 9259 0.092.2 58.0 57.1 (50.163.9) 1906.5 (p<0.001) 97.7 (97.398.0) 13.794.6
Women 29 8267 20.592.2 70.6 66.4 (59.173.3) 1283.4 (p<0.001) 97.8 (97.498.2) 25.496.4
Men 13 849 9.188.5 43.0 43.6 (31.456.2) 150.1 (p<0.001) 92.0 (88.194.6) 4.388.7
Mixed 3 143 0.045.0 21.0 18.2 (0.543.4) 29.1 (p<0.001) 93.1 (83.397.2) 0.0100
Higher-risk populations 40 13,476 4.399.0 63.7 61.4 (53.469.1) 3264.9 (p<0.001) 98.8 (98.798.9) 13.498.2
FSWs 39 13,036 4.399.0 65.0 62.5 (54.870.0) 2898.0 (p<0.001) 98.7 (98.598.8) 15.797.9
MSM 1x 440   22.3 (18.526.3)x - - -
HIV-negative populations 51 38,533 6.089.0 44.0 47.4 (43.251.5) 3198.9 (p<0.001) 98.4 (98.298.6) 19.775.9
Women 34 33,699 17.089.0 46.5 52.1 (47.556.7) 2283.9 (p<0.001) 98.6 (98.398.7) 25.678.0
Men 13 3119 11.080.4 31.6 37.9 (30.246.0) 227.1 (p<0.001) 94.7 (92.596.3) 10.969.8
Mixed 4 1715 6.057.9 35.6 35.8 (23.049.8) 84.4 (p<0.001) 96.4 (93.598.1) 0.093.1
HIV-positive individuals and
in individuals in HIV dis-
cordant couples
42 15,521 17.595.2 70.2 71.3 (66.575.9) 1514.7 (p<0.001) 97.3 (96.897.7) 38.994.9
Women 20 6183 42.095.2 79.7 76.7 (70.182.7) 587.4 (p<0.001) 96.8 (95.997.5) 43.297.9
Men 15 4306 44.094.2 61.4 72.0 (63.779.6) 311.0 (p<0.001) 95.5 (93.996.7) 36.296.8
Mixed 7 5032 17.570.2 62.3 54.6 (47.461.8) 108.9 (p<0.001) 94.5 (91.096.6) 31.077.1
STI clinic attendees and
symptomatic populations
72 11,996 14.793.3 60.7 61.2 (56.565.9) 1826.8 (p<0.001) 96.1 (95.696.6) 22.993.0
Women 26 4038 38.093.3 75.3 69.2 (62.775.4) 393.3 (p<0.001) 93.6 (91.895.1) 35.294.7
Men 38 6585 14.786.4 56.6 52.9 (46.958.8) 791.4 (p<0.001) 95.3 (94.396.1) 18.885.6
Mixed 8 1373 85.085.0 79.4 75.8 (68.582.5) 35.9 (p<0.001) 80.5 (62.389.9) 51.893.7
Other populations 16 6506 11.289.4 48.1 50.3 (41.958.7) 546.4 (p<0.001) 97.3 (96.597.9) 17.458.7
Women 9 5642 27.889.4 48.7 53.8 (45.661.9) 260.2 (p<0.001) 96.9 (95.697.9) 24.881.5
Men 3 803 11.238.6 23.7 23.4 (10.539.4) 48.2 (p<0.001) 95.9 (91.098.1) 0.0100
Mixed 4 61 46.783.3 75.7 71.1 (54.485.5) 5.1 (p = 0.164) 41.2 (0.080.2) 13.7100
* Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in seroprevalence.
y I2: a measure that assesses the magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather than chance.
z Prediction interval: a measure that estimates the distribution (95% interval) of true seroprevalence around the estimated mean.
x No meta-analysis was done due to the small number of studies (n < 3).
{ Symptomatic populations include patients with clinical manifestations related to an STI.
Abbreviations: CI = Confidence interval, FSWs = Female sex workers, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, MSM = Men who have sex
with men, STI = Sexually transmitted disease.
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Table 3
Pooled mean estimates for herpes simplex virus type 2 seroprevalence among general populations in sub-Saharan Africa.
Population classification Outcome
measures
Sample size HSV-2 seroprevalence (%) Pooled mean HSV-2
seroprevalence
Heterogeneity measures
Total n Total N Range Median Mean (%) (95% CI) Q* (p-value) I2y (%) (95% CI) Prediction
intervalz (%)
African countries
Benin 16 3991 1.057.0 28.0 24.6 (17.132.9) 447.1 (p<0.001) 96.6 (95.674.4) 1.163.5
Burkina Faso 14 5932 4.140.5 20.3 19.5 (14.724.8) 297.3 (p<0.001) 95.6 (94.096.8) 3.543.8
Cameroon 23 2309 3.090.9 59.0 53.6 (40.966.2) 804.9 (p<0.001) 97.3 (96.697.8) 2.499.6
Ethiopia 10 2444 7.959.5 28.5 27.3 (16.839.3) 277.4 (p<0.001) 96.8 (95.497.7) 0.273.7
Kenya 71 34,605 1.991.3 42.4 39.9 (34.345.9) 8018.6 (p<0.001) 99.1 (99.199.2) 3.086.2
Malawi 55 9571 0.087.5 50.0 45.1 (38.252.0) 2192.8 (p<0.001) 97.5 (97.297.8) 4.590.2
Nigeria 14 2205 8.761.3 29.3 28.5 (16.142.7) 486.9 (p<0.001) 97.3 (96.598.0) 0.085.6
South Africa 79 44,449 1.592.5 31.0 34.1 (27.341.9) 19,846.8 (p<0.001) 99.6 (99.699.6) 0.093.4
Tanzania 41 18,731 7.068.0 36.8 37.4 (33.741.1) 1008.2 (p<0.001) 96.0 (95.396.7) 16.161.6
Uganda 59 52,216 9.990.7 53.4 50.5 (44.256.8) 12,120.9 (p<0.001) 99.5 (99.599.6) 8.592.1
Zambia 42 25,973 1.080.0 41.5 36.3 (28.244.8) 7909.4 (p<0.001) 99.5 (99.499.5) 0.388.7
Zimbabwe 42 20,530 0.171.0 30.6 26.0 (17.535.5) 8678.9 (p<0.001) 99.5 (99.599.6) 0.088.6
Other countriesx 41 7585 2.697.4 22.2 31.1 (24.538.1) 1564.8 (p<0.001) 97.4 (97.097.8) 0.177.3
African subregions
Eastern Africa 188 110,399 1.991.3 42.4 41.9 (38.445.3) 25,111.0 (p<0.001) 99.3 (99.299.3) 4.985.6
Southern Africa 226 100,925 0.092.5 40.3 35.8 (31.640.0) 43,422.5 (p<0.001) 99.5 (99.599.5) 0.092.9
Western Africa 68 16,005 1.097.4 21.9 25.0 (20.929.4) 2442.9 (p<0.001) 97.3 (96.997.6) 1.263.7
Central Africa 25 3212 3.090.9 59.0 52.4 (40.464.3) 1065.0 (p<0.001) 97.7 (97.398.1) 2.698.9
Age group
<20 years 88 40,217 0.046.0 11.0 12.4 (10.614.3) 2419.1 (p<0.001) 96.4 (96.096.8) 1.032.6
2030 years 112 49,099 2.991.3 36.8 34.2 (30.737.8) 7583.3 (p<0.001) 98.5 (98.498.6) 5.072.7
3040 years 69 26,412 16.490.4 60.6 57.1 (54.863.3) 3210.2 (p<0.001) 97.9 (97.698.1) 24.689.2
4050 years 48 12,470 20.092.5 61.7 64.6 (59.569.5) 1445.1 (p<0.001) 96.7 (96.297.2) 29.892.5
>50 years 15 4054 39.680.9 60.6 58.2 (50.365.9) 321.3 (p<0.001) 95.6 (94.196.8) 26.386.8
Mixed 175 98,289 0.197.4 35.0 36.2 (32.140.3) 31,073.2 (p<0.001) 99.4 (99.499.5) 0.487.7
Year of publication category
2005 124 27,633 1.090.9 45.5 42.1 (38.146.2) 5477.8 (p<0.001) 97.8 (97.697.9) 6.283.8
20052015 283 142,060 0.097.4 38.4 35.7 (32.638.9) 42,499.0 (p<0.001) 99.3 (99.399.3) 0.686.0
>2015 100 60,848 1.592.5 35.8 35.9 (30.141.8) 23,039.3 (p<0.001) 99.6 (99.599.6) 0.090.9
All studies 507 230,541 0.097.4 39.5 37.3 (34.939.7) 73,247.9 (p<0.001) 99.3 (99.399.3) 0.788.0
* Q: the Cochran's Q statistic is a measure assessing the existence of heterogeneity in seroprevalence.
y I2: a measure that assesses the magnitude of between-study variation that is due to actual differences in seroprevalence across studies rather than chance.
z Prediction interval: a measure that estimates the distribution (95% interval) of true seroprevalence around the estimated mean.
x Other countries: Chad, Cote D'Ivoire, Eritrea, Gabon, Gambia, Ghana, Mali, Namibia, Rwanda, Senegal.
Abbreviations: CI = Confidence interval, HSV-2 = Herpes simplex virus type 2.
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able explained 57.5% of seroprevalence variation and included
population type, age group, sex, African subregion, national
income, assay type, sampling method, response rate, and year of
publication category (Table 4). Compared to general populations
that had the lowest seroprevalence, seroprevalence was highest
in HIV-positive individuals and in individuals in HIV discordant
couples [adjusted risk ratio (ARR) of 2.17 (95% CI: 1.782.65)],
followed by STI clinic attendees and symptomatic populations,
higher-risk populations, intermediate-risk populations, and HIV-
negative populations.
Compared to women, men had a 0.61-fold (95% CI: 0.560.67)
lower seroprevalence. Seroprevalence increased rapidly with age
among young people, but the increase plateaued by age 4050 years.
Seroprevalence was highest in Eastern Africa, followed by Southern
Africa, Central Africa, and lowest in Western Africa. National income
was not associated with seroprevalence.
Studies that had a lower or unknown response rate had a
higher seroprevalence. Meanwhile, assay type, study sample size,
and study sampling method were not associated with
seroprevalence.
Compared to those published before the year 2005, studies pub-
lished from 2006 to 2015 [ARR of 0.85 (95% CI: 0.760.96)] and after
2015 [ARR of 0.80 (95% CI: 0.690.93)] had lower seroprevalence.
The model including year of publication as a linear term (Table 4)
showed similar results and indicated declining seroprevalence with
time [ARR of 0.98 (95% CI: 0.970.99)]. The model explained 57.5% of
seroprevalence variation.Sensitivity analyses including year of data collection as a categori-
cal variable or as a linear term (replacing year of publication) yielded
similar results (Table S9).
3.6. Overview and meta-analyses of HSV-2 isolation in genital ulcer
disease and in genital herpes
Table S10 summarizes extracted proportions of HSV-2 detected in
GUD and in genital herpes. In GUD cases (n = 31), the proportion of
HSV-2 ranged from 8.3 to 100% with a median of 49.1% and a pooled
mean proportion of 50.7% (95% CI: 44.756.8%) (Table 5). Among
women (n = 8), it ranged from 35.0 to 100% with a median of 49.5%
and a pooled proportion of 59.0% (95% CI: 44.772.6%), and among
men (n = 13), it ranged from 8.3 to 72.2% with a median of 49.1% and
a pooled proportion of 47.3% (95% CI: 37.257.5%).
In genital herpes cases (n = 11), the proportion of HSV-2 ranged
between 53.0100% with a median of 100% and a pooled mean pro-
portion of 97.3% (95% CI: 84.4100%) (Table 5). No study distin-
guished between primary and recurrent genital herpes.
These meta-analyses showed evidence of heterogeneity (p-val-
ue<0.001, I2>50%, and wide prediction intervals). Forest plots are in
Fig. 2.
3.7. Quality assessment
Quality assessment of diagnostic methods excluded 51 publica-
tions due to potential problems in the diagnostic assays employed
(Fig. 1). Quality assessment of included seroprevalence measures is
Table 4
Univariable and multivariable meta-regression analyses for herpes simplex virus type 2 seroprevalence in sub-Saharan Africa.
Outcome
measures
Sample size Univariable analysis Multivariable analysis




Model 1* Model 2y
ARR (95% CI) p-value ARR (95% CI) p-value
Population
characteristics
Population type General populations 507 230,541 1.00  <0.001 12.9 1.00  1.00 
Intermediate-risk populations 45 9259 1.73 (1.352.21) <0.001 1.50 (1.241.81) <0.001 1.49 (1.231.81) <0.001
Higher-risk populations 40 13,476 1.70 (1.312.20) <0.001 1.58 (1.281.94) <0.001 1.59 (1.291.96) <0.001
HIV negative populations 51 38,533 1.41 (1.121.78) 0.003 1.31 (1.071.59) 0.008 1.30 (1.071.59) 0.008
HIV positive individuals and
individuals in HIV discordant
couples
42 15,521 2.18 (1.702.80) <0.001 2.17 (1.782.65) <0.001 2.18 (1.782.66) <0.001
STI clinic attendees and symp-
tomatic populations
72 11,996 1.88 (1.542.28) <0.001 1.76 (1.492.08) <0.001 1.78 (1.512.10) <0.001
Other populations 16 6506 1.53 (1.032.27) 0.033 1.22 (0.901.65) 0.179 1.24 (0.921.68) 0.150
Age group <20 years 108 42,984 1.00  <0.001 32.6 1.00  1.00 
2030 years 144 55,344 2.49 (2.073.00) <0.001 2.51 (2.152.93) <0.001 2.53 (2.172.94) <0.001
3040 years 84 27,875 4.26 (3.465.24) <0.001 4.44 (3.745.28) <0.001 4.46 (3.755.30) <0.001
4050 years 52 12,650 4.62 (3.645.86) <0.001 5.27 (4.326.44) <0.001 5.27 (4.316.43) <0.001
>50 years 16 4127 4.30 (2.966.24) <0.001 4.80 (3.526.56) <0.001 4.64 (3.406.33) <0.001
Mixed ages 369 182,852 3.10 (2.643.64) <0.001 2.37 (2.052.73) <0.001 2.38 (2.072.75) <0.001
Sex Women 447 204,899 1.00  <0.001 4.7 1.00  1.00 
Men 269 100,000 0.68 (0.600.78) <0.001 0.61 (0.560.67) <0.001 0.61 (0.560.67) <0.001
Mixed sexes 57 20,933 0.89 (0.701.12) 0.337 0.78 (0.650.94) 0.011 0.80 (0.660.96) 0.018
African subregion Eastern Africa 298 144,196 1.00  <0.001 3.3 1.00  1.00 
Southern Africa 319 128,395 0.82 (0.720.94) 0.006 0.85 (0.760.96) 0.014 0.86 (0.760.97) 0.015
Western Africa 94 21,301 0.63 (0.520.77) <0.001 0.60 (0.520.70) <0.001 0.61 (0.530.71) <0.001
Central Africa 48 5832 1.01 (0.781.31) 0.909 0.75 (0.610.93) 0.009 0.75 (0.610.93) 0.009
Mixed regions 14 26,225 1.23 (0.791.91) 0.347 1.01 (0.472.17) 0.965 1.02 (0.472.18) 0.955
National income LIC 326 123,156 1.00  0.027 0.7 1.00  1.00 
LMIC 285 107,905 0.86 (0.750.98) 0.030 0.95 (0.861.05) 0.385 0.96 (0.871.07) 0.540
UMIC 145 63,908 0.89 (0.751.05) 0.195 1.12 (0.961.31) 0.131 1.14 (0.971.33) 0.093
Mixed 17 30,863 1.35 (0.902.03) 0.141 0.84 (0.421.67) 0.622 0.86 (0.431.71) 0.670
Study methodology
characteristics
Assay type Western Blot 82 19,787 1.00  0.089 0.5 1.00  1.00 
ELISA 681 304,639 0.86 (0.711.05) 0.157 1.02 (0.871.20) 0.730 1.03 (0.881.21) 0.663
Rapid test 10 1406 0.55 (0.310.97) 0.041 0.71 (0.461.08) 0.111 0.74 (0.481.12) 0.162
Sample sizez 100 740 324,163 1.00  0.634 0.0    
<100 33 1669 1.07 (0.791.45) 0.654    
Sampling method Probability based 311 165,963 1.00  <0.001 3.6 1.00  1.00 
Non-probability based 462 159,869 1.35 (1.201.53) <0.001 1.06 (0.941.19) 0.289 1.06 (0.941.18) 0.303
Response rate 80% 255 142,489 1.00  <0.001 4.0 1.00  1.00 
<80% 153 57,722 0.95 (0.801.12) 0.564 1.18 (1.041.34) 0.007 1.19 (1.051.35) 0.007
Unclear 365 125,621 1.34 (1.171.53) <0.001 1.30 (1.161.45) <0.001 1.29 (1.151.44) <0.001
Temporal variables Year of publication
category
<2005 218 38,609 1.00  <0.001 3.1 1.00   
20062015 422 208,948 0.86 (0.740.98) 0.032 0.85 (0.760.96) 0.009  
>2015 133 78,275 0.67 (0.560.80) <0.001 0.80 (0.690.93) 0.005  
Year of publication 773 325,832 0.97 (0.970.98) <0.001 <0.001 2.9   0.98 (0.970.99) 0.006
* Variance explained by multivariable model 1 (adjusted R2) = 57.47%.
y Variance explained by multivariable model 2 (adjusted R2) = 57.50%.
z Sample size denotes the sample size of each study population found in the original publication.
Abbreviations: ARR = Adjusted risk ratio, CI = Confidence interval, ELISA = Enzyme-linked immunosorbent type-specific assay, HIV = Human immunodeficiency virus, HSV-2 = Herpes simplex virus type 2, LIC = Low-income country,











Pooled proportions of herpes virus type 2 (HSV-2) virus isolation in clinically diagnosed GUD and in clinically diagnosed genital herpes in Africa.
Population type Outcome
measures
Sample size Proportion of HSV-2 isolation (%) Pooled proportion
of HSV-2 isolation (%)
Heterogeneity measures
Total n Total N Range Median Mean (95% CI) Q* (p-value) I2y (%) (95% CI) Prediction
Intervalz (%)
Patients with GUD 31 4296 8.3100 49.1 50.7 (44.756.8) 423.6 (p<0.001) 92.9 (91.094.4) 19.781.5
Women 8 816 35.0100 49.5 59.0 (44.772.6) 88.1 (p<0.001) 92.1 (86.795.2) 13.0100
Men 13 1915 8.372.2 49.1 47.3 (37.257.5) 225.1 (p<0.001) 94.7 (92.496.2) 11.484.8
Mixed sexes 10 1565 22.473.0 50.0 49.1 (39.059.2) 110.3 (p<0.001) 91.8 (87.194.8) 15.583.2
Patients with genital herpes 11 1380 53.0100 100 97.3 (84.4100) 586.5 (p<0.001) 98.3 (97.898.7) 22.8100
Men 6 715 53.0100 100 97.3 (73.4100) 318.8 (p<0.001) 98.4 (97.798.9) 0.0100
Mixed sexes 5 665 91.4100 85.4 97.8 (91.9100) 23.9 (p<0.001) 83.3 (62.092.6) 66.2100
* Q: The Cochran's Q statistic is a measure assessing the existence of heterogeneity in pooled outcome measures, here proportions of HSV-2 virus isolation.
y I2: A measure assessing the magnitude of between-study variation that is due to true differences in proportions of HSV-2 virus isolation across studies rather than sampling
variation.
z Prediction interval: A measure quantifying the distribution 95% interval of true proportions of HSV-2 virus isolation around the estimated pooled mean.
Abbreviations: CI = Confidence interval, GUD = Genital ulcer disease, HSV-2 = Herpes simplex virus type 2.
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sion, 88 studies (27.3%) and 85 studies (26.4%) had low ROB in sam-
pling methods and in the response rate domains, respectively.
Twenty-three studies (7.1%) had high ROB in both quality domains.
4. Discussion
This systematic review presented a detailed assessment of HSV-2
epidemiology in sub-Saharan Africa. HSV-2 seroprevalence in sub-
Saharan Africa, estimated at 37%, was much higher than that esti-
mated in other global regions, from 8% in Europe to 18% in the Ameri-
cas [1]. Strikingly, the results demonstrate that HSV-2 seroprevalence
has been declining by about 2% per year over the last three decades
(Table 4). This decline is consistent with observed declines in HIV epi-
demics in SSA during the same period [62]. Drivers of the decline in
HIV prevalence have been subject to debate, with various mecha-
nisms posited, including natural epidemic dynamics [63], increased
HIV-associated mortality [64,65], impact of interventions [65], het-
erogeneity in host susceptibility to HIV infection [66,67], and reduc-
tions in sexual risk behavior [65,6871]. Considering that HSV-2
seroprevalence provides an objective proxy biomarker of population-
level sexual risk behavior [1924], our finding of rapidly declining
HSV-2 seroprevalence suggests that sexual risk behavior has been
declining, and that this decline has reduced the transmission of both
HIV and HSV-2 infections. With evidence of HSV-2 infection increas-
ing risk of HIV acquisition and transmission [1013], declining HSV-
2 incidence may have also contributed to the decline in HIV incidence
in SSA.
Despite declining HSV-2 transmission in SSA, the incidence
rate is still high (Table 1), and much higher than that found else-
where in the world [1]. For instance, the incidence rate in the
United States (<1 per 100 person-years) [72] is an order of mag-
nitude lower than in SSA. The results further demonstrate that
age has a profound effect in HSV-2 epidemiology—age alone
accounted for 30% of the seroprevalence variation (Table 4). HSV-
2 infection in SSA is typically acquired at a young age, not long
after sexual debut, especially for women, manifested in rapidly
increasing seroprevalence with age before plateauing at high lev-
els by ages 4050 (Tables 1,3,4, and S8).
Population risk classification is an important determinant in HSV-
2 epidemiology, accounting for 13% of seroprevalence variation
(Table 4). Both incidence rate and seroprevalence were much higher
in specific at-risk populations, such as female sex workers (Tables 2
and 4), with both measures displaying the “classical hierarchy” of STI
exposure by sexual risk behavior, seen with other STIs [73,74].Despite its prominence amongst higher-risk populations, HSV-2
infection is also widely disseminated in SSA with high levels of infec-
tion even in the lower-risk general population, in which over 25% of
men and nearly 50% of women are infected (Tables 2 and 4).
Although HSV-2 seroprevalence is high everywhere in SSA, there
are still considerable variations by subregion. Infection levels were
highest in Eastern Africa followed by Southern Africa, Central Africa,
and lowest in Western Africa (Table 4). Incidentally, this pattern is
also seen for HIV infection with Eastern Africa and Southern Africa
being most affected and Western Africa least affected [75,76]. This
further suggests a strong link between HSV-2 and HIV epidemiologies
[24], reflecting a similar mode of transmission and hinting at a bio-
logical/epidemiological synergy [1014]. The results further demon-
strate that women are almost twice as likely to be infected as men
(Table 4), reflecting a higher bio-anatomical susceptibility to the
infection [77,78].
Another finding of this study is that HSV-2 infection causes half
the GUD cases in SSA (Table 5), confirming that this infection is the
main cause of this disease in this part of the world where nearly
60 million individuals are estimated to be affected with HSV-related
GUD [79]. Although HSV-2 seroprevalence is declining (Table 4), it
will likely remain the main cause of GUD in SSA, as other causes such
as syphilis have also been declining [80,81]. HSV-2 infection (as
opposed to HSV-1 infection) also accounted for nearly all cases of
genital herpes (>97%; Table 5). This finding is presumably due to the
nature of HSV-1, which is widely acquired in childhood in SSA by oral
transmission [33], and distinguishes this region from other global
regions where there is an increasing role for HSV-1 in genital herpes
[3336], with some countries already observing HSV-1 as the cause
of a large proportion of first-episode genital herpes cases [3336].
This study had limitations, principally the unavailability of data
for 15 of 45 African countries. There were also less data for Central
and Western Africa than for Eastern and Southern Africa, in addition
to data for seroprevalence eclipsing those of GUD and genital herpes.
Despite these limitations, a large volume of data was available to suf-
ficiently power an array of analyses. Included studies exhibited het-
erogeneity (Tables 2, 3, and S8); however, more than half of this
heterogeneity (57%) was subsequently explained through meta-
regression (Table 4). Studies differed by assay type, sample size, sam-
pling method, and response rate, yet none of these characteristics
appeared to affect seroprevalence, with the exception of response
rate, where studies with lower or unknown response rates had a
higher seroprevalence (Table 4). Overall, these limitations should not
pose a barrier to the critical interpretation of this study's results or
findings.
Fig. 2. Forest plots presenting the outcomes of pooled mean proportions of HSV-2 virus isolation in clinically diagnosed genital ulcer disease (GUD) and in clinically diagnosed geni-
tal herpes in sub-Saharan Africa.
Abbreviations: HSV-2 = Herpes simplex virus type 2.
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SSA. Yet, HSV-2 incidence and seroprevalence remain at high lev-
els, with over a third of the population being infected. Age and
subregion in SSA play a critical role in HSV-2 epidemiology and
explain much of the observed variation in seroprevalence. The
geographical distribution of this infection was similar to that of
HIV infection, and the declines in HSV-2 seroprevalence mirrored
those for HIV prevalence. These findings suggest that reductions
in sexual risk behavior following the massive expansion of theHIV epidemic in this continent have contributed to reductions in
both HIV and HSV-2, and suggest that the biological/epidemio-
logic synergy may have been an influencing factor. HSV-2 infec-
tion was found to be the etiological cause of half the GUD cases
in this region, and virtually all cases of genital herpes. These find-
ings demonstrate the urgent need for both prophylactic and ther-
apeutic HSV-2 vaccines to tackle the disease burden of this
infection [82], and argue for further acceleration of ongoing
efforts for vaccine development [26,27,83].
Fig. 2. Continued.
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